The Experts below are selected from a list of 1908 Experts worldwide ranked by ideXlab platform
Eric R Braverman - One of the best experts on this subject based on the ideXlab platform.
-
“Cold” X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, Eric R BravermanAbstract:Background Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. Methods For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. Results A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
"Cold" X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: An uncontrolled pilot study
BMC research notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
cold x5 hairlaser used to treat male Androgenic Alopecia and hair growth an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly significant (p-value = 0.0003). Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement with other low laser hair devices requires intensive further investigation. NCT02067260
Kenneth Blum - One of the best experts on this subject based on the ideXlab platform.
-
“Cold” X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, Eric R BravermanAbstract:Background Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. Methods For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. Results A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
"Cold" X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: An uncontrolled pilot study
BMC research notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
cold x5 hairlaser used to treat male Androgenic Alopecia and hair growth an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly significant (p-value = 0.0003). Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement with other low laser hair devices requires intensive further investigation. NCT02067260
Margaret A Madigan - One of the best experts on this subject based on the ideXlab platform.
-
“Cold” X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, Eric R BravermanAbstract:Background Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. Methods For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. Results A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
"Cold" X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: An uncontrolled pilot study
BMC research notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
cold x5 hairlaser used to treat male Androgenic Alopecia and hair growth an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly significant (p-value = 0.0003). Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement with other low laser hair devices requires intensive further investigation. NCT02067260
Raquel Lohmann - One of the best experts on this subject based on the ideXlab platform.
-
“Cold” X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, Eric R BravermanAbstract:Background Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. Methods For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. Results A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
"Cold" X5 Hairlaser™ used to treat male Androgenic Alopecia and hair growth: An uncontrolled pilot study
BMC research notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value
-
cold x5 hairlaser used to treat male Androgenic Alopecia and hair growth an uncontrolled pilot study
BMC Research Notes, 2014Co-Authors: Kenneth Blum, Margaret A Madigan, Raquel Lohmann, David Han, Eric R BravermanAbstract:Various trials have been conducted on the management and treatment of Androgenic Alopecia (AGA) or male pattern hair loss using a variety of laser and light sources. For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type. A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male Androgenic Alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly significant (p-value = 0.0003). Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement with other low laser hair devices requires intensive further investigation. NCT02067260
Stana Păunică - One of the best experts on this subject based on the ideXlab platform.
-
Finasteride and Androgenic Alopecia; from therapeutic options to medical implications
The Journal of dermatological treatment, 2019Co-Authors: Ion G. Motofei, David L. Rowland, Stana Păunică, Mircea Tampa, Maria-isabela Sarbu, Madalina-irina Mitran, Cristina-iulia Mitran, Anca Pantea Stoian, Camelia Cristina Diaconu, Simona R GeorgescuAbstract:Androgenic Alopecia (AGA) is an esthetic condition with varying psycho-social implications, easily accepted by some patients and tolerated only with difficulty by others. Modern therapeutic options such as 5α-reductase inhibitors have significant outcomes, but also exert significant side effects in a subset of patients. The literature describes three distinct situations regarding finasteride administration, a compound largely used for AGA. Some studies show finasteride to be very safe with minimal or no side effects. Other studies take a more cautious approach, recognizing such side effects but, at the same time, considering the putative relationship between finasteride and adverse effects to be disputable, given that placebo administration in AGA is associated with relatively similar or even more severe side effects. Finally, some authors/studies are concerned that, when compared to placebo, finasteride administration may result in side effects with greater frequency and severity, and sometimes that persist even after treatment cessation in the form of post-finasteride syndrome. Several factors presented in this paper appear to explain finasteride inconsistency regarding its therapeutic and side effects. Such factors should be further investigated and used to categorize subjects into distinct subgroups, either predisposed to adverse reactions or more tolerant of the finasteride administration.
-
Androgenic Alopecia; the risk–benefit ratio of Finasteride
Ion Motofei Carol Davila University, 2018Co-Authors: David L. Rowland, Ion G. Motofei, Ioana Păunică, Petrișor Banu, Mihaela F. Nistor, Stana Păunică, Vlad D. ConstantinAbstract:Finasteride is currently approved and largely used as a therapeutic option for androgenetic Alopecia. Apparently a safe drug and effective at the onset, several concerns appeared over time regarding the frequency and magnitude of finasteride adverse effects, which in some cases seem to be even irreversible. This paper presents administration of finasteride in Androgenic Alopecia from two distinct perspectives. On one hand, Androgenic Alopecia is a condition that affects especially the self-image and esteem, aspects that are subjective, namely changeable and thus relative. On the other hand, this condition presents a multifactorial etiology, androgens being only in part involved. In addition, androgens have their own physiological roles within the body, so that any Androgenic suppression should be carefully advised. Yet, adverse effects induced by Finasteride are only in part documented and treatable. Finally, alternative therapeutic approaches (like topical finasteride) become available, so that the oral administration of Finasteride for Androgenic Alopecia should be in our opinion reevaluated. As a conclusion, a very detailed and informed discussion should take place with such patients accepting to start a therapy with finasteride for Androgenic Alopecia
-
are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male Androgenic Alopecia
Experimental Dermatology, 2016Co-Authors: Ion G. Motofei, David L. Rowland, Mircea Tampa, Bogdan C. Baleanu, Simona R Georgescu, Stana PăunicăAbstract:Sexual side effects of finasteride seem to be redoubtable, being encountered not only during therapy but also after treatment cessation. Consequently, any possible clinical/paraclinical elements that might predict these adverse effects would be useful in the selection of a therapeutic strategy for male Androgenic Alopecia. Previous published studies show that some compounds that interfere with sexual hormones can decrease sexual activation and response, according to hand preference (as reported for finasteride and tamoxifen) and according to sexual orientation (as noted for bicalutamide). Our preliminary published data and the arguments presented here suggest that these two individual parameters might be used by dermatologists in the therapeutic approach of male Androgenic Alopecia, so as to alert specific subsets of men, prior to treatment, of the potential increased risk for developing adverse effects to finasteride.
-
Finasteride adverse effects in subjects with Androgenic Alopecia: A possible therapeutic approach according to the lateralization process of the brain.
The Journal of dermatological treatment, 2016Co-Authors: Ion G. Motofei, David L. Rowland, Mircea Tampa, Vlad Denis Constantin, Bogdan C. Baleanu, Simona R Georgescu, Daniela Luiza Baconi, Emil Stefanescu, Cristian Balalau, Stana PăunicăAbstract:Nowadays, finasteride is a relatively frequently prescribed drug in the therapeutic management of male Androgenic Alopecia. The reported adverse effects are notable in some patients, consisting in signs and symptoms that are encountered both during finasteride administration and after treatment cessation. Clinical and imagistic data show that cognition and sexuality are two distinct but interrelated environmental functions, most probable due to lateralization process of the brain. Specific for our topic, relatively recent published studies found that frequency and severity of finasteride adverse effects could be interrelated with hand preference and sexual orientation of the respective subjects. This paper tries to explain/support this interrelation through a psychophysiologic approach, to suggest how this premise could be further proved in dermatological practice, and to highlight its relevance in respect to therapeutic approach of male Androgenic Alopecia. As a possible therapeutic application, subjects having preference for a certain sexual orientation and/or predisposition for a given dominant hand could be advised before finasteride administration, that present an increased risk/sensitivity to develop adverse effects. Finally, even if finasteride and post-finasteride symptoms overlap to a large extent they should be, however, viewed as distinct physiopathologic entities, which could require perhaps different therapeutic approaches.
-
198 Dutasteride for men with Androgenic Alopecia unresponsive to finasteride
Journal of Investigative Dermatology, 2016Co-Authors: Ion G. Motofei, David L. Rowland, Stana Păunică, Simona Roxana Georgescu, Mircea Tampa, Vlad Denis Constantin, Bogdan C. Baleanu, Ioanel SinescuAbstract:198 Dutasteride for men with Androgenic Alopecia unresponsive to finasteride IG Motofei, DL Rowland, SR Georgescu, M Tampa, VD Constantin, S Paunica, BC Baleanu and I Sinescu 1 Surgery and Urology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, 2 Psychology, Valparaiso University, Valparaiso, IN, 3 Dermatology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, 4 Urology, Hermann-Josef KH, Kreisfreie Stadt Aachen Area, Germany and 5 Urology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania About 30% of men with Androgenic Alopecia have no significant improvement at six months after Finasteride administration. For this subgroup, dutasteride could represent an alternative therapy being more efficient and with reasonable adverse effects, according to some authors. Starting from this perspective, we intended to verify the dutasteride efficiency and side effects in Androgenic Alopecia, on unresponsive men to finasteride. From ninety-two men treated with Finasteride (1 mg/ day) for Androgenic Alopecia, twenty three subjects finished the treatment with no result on the target hair area, as confirmed by global photograph assessment and phototrichogram. From those 23 unresponsive men, 16 started a new treatment with dutasteride 0.5 mg/ day, being evaluated after six months again by dermatologists and urologists. In response to dutasteride, 9 subjects (56.25%) registered a significant improvement (hair density/ thickness) after six months, according to photograph and phototrichogram assessments. The other 7 subjects were appreciated as unresponsives to dutasteride, no aggravation being reported. Dutasteride adverse effects were reasonable, consisting in transient erectile dysfunction (in two responsive patients) and erectile dysfunction plus slight depressive episode (in 1 unresponsive patient). In contrast to Finasteride, dutasteride inhibits both type I and II of 5-a reductase enzyme, being able to ameliorate Androgenic Alopecia in some subjects who registered no improvement after finasteride administration. Dutasteride could be thus viewed as a secondary therapeutic option for Androgenic Alopecia, and a possible first therapeutic choice at subjects with predisposed (anticipated) finasteride side effects. 199 Hand preference and sexual orientation as useful elements to predict finasteride side effects in male Androgenic Alopecia DL Rowland, IG Motofei, SR Georgescu, M Tampa and I Sinescu 1 Psychology, Valparaiso University, Valparaiso, IN, 2 Surgery and Urology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania, 3 Dermatology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania and 4 Urology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania This study further investigated the distribution of finasteride adverse effects (according to hand preference and sexual orientation) on men treated for male Androgenic Alopecia, based on the existing interrelation among sexual hormones, pheromones, cognitive and sexual laterality of information processing. Finasteride 1 mg daily, human axillary pheromones, questionnaires regarding hand preference (Edinburgh Handedness Inventory) and related to sexual orientation/ behavior were used, to delineate within the brain hormonal and pheromonal neuromodulation of sexuality on 68 men with Androgenic Alopecia. Participants’ responses delineated four distinct groups. Group Awith 12 men, involving especially the left hemibrain: sensitive to female axillary pheromones, left nostril and right visual hemifield, with left hand preference and predominantly heterosexuals (9 men). Group B (16 men) related to the right hemibrain: sensitive to male axillary pheromones, right nostril, and left visual hemifield, with right hand preference, six being homosexuals and ten heterosexuals. Group C with 11 men related to the left hemibrain: sensitive to androgens, with right hand preference and heterosexuals. Group D (29 men) related to right hemibrain: sensitive to estrogens, with left hand preference and mixed sexual orientation (17 heterosexuals and 12 homosexuals). Finasteride adverse effects were encountered especially in groups C (on 8 men) and group D (on 7 men), specifically on subjects who were either right handed heterosexuals or left handed homosexuals. In psycho-physiological terms, androgens seem to modulate only the left hemibrain, and more precisely, the left dorsal thalamic route.